Cerenis Therapeutics Adds Three Pharmaceutical Industry Veterans to its Clinical, Regulatory Affairs and Business Development Te

Cerenis Therapeutics Adds Three Pharmaceutical Industry Veterans to its Clinical, Regulatory Affairs and Business Development Teams

Tom Brya, MBA, J. Christopher Pue, RPh, MBA, and Cynthia Sundell, PhD bring broad cardiovascular sector expertise to Cerenis

TOULOUSE, FRANCE & ANN ARBOR, MICHIGAN, SEPTEMBER  2nd, 2009-Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing novel HDL therapies to treat cardiovascular and other metabolic diseases, today announced the expansion of its team to include Tom Brya,  J. Christopher Prue and Cynthia Sundell. With deep experience in, respectively, business development, regulatory affairs and clinical discovery, these industry veterans will provide broad support for Cerenis' ongoing drug discovery and development efforts.

Tom Brya joins Cerenis as Senior Vice President of Business Development. Tom has supported business growth and expansion at Pharmacia, Monsanto/Searle, Cardinal Health, and KV Pharmaceutical.

With deep experience in the cardiovascular space, he has also led more than 200 deals in M&A, licensing, co-promotion, drug delivery and financing projects with closed deals across 15 countries. Formerly, Tom was vice president and general manager for a biologic CMO startup at Cardinal Health (now part of Catalent Pharma Services). Tom holds an MBA (from Northwestern Kellogg School of Management), MST and CPA. 

J. Christopher Prue, RPh, MBA, joins Cerenis as Vice President of Regulatory Affairs. A 30-year veteran of the pharmaceutical industry, Christopher formerly held roles at AtheroGenics, Purdue Pharma, Incara Pharmaceuticals, Glaxo Wellcome, and The Upjohn Company. Christopher brings a broad knowledge of regulatory operations to Cerenis and will oversee the company's regulatory, pharmacovigilance and quality assurance efforts.

Cynthia Sundell, PhD, brings more than 14 years' experience to her new role as Vice President of Drug Development at Cerenis. Formerly Cindi led discovery efforts at AtheroGenics, where she supported the delivery of multiple compounds to clinical development in the areas cardiovascular, metabolic and chronic inflammatory diseases.

"We are very pleased to welcome Cindi, Christopher and Tom to our world-class team here at Cerenis," said Jean-Louis Dasseux, PhD, MBA, president and CEO of Cerenis. "Their stellar track records and tremendous cardiovascular sector expertise will play crucial roles in both our ongoing and new clinical development efforts."

About Cerenis Therapeutics

Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL therapies for the treatment of cardiovascular and metabolic diseases.

Based on pioneering research conducted by Cerenis' team of world leaders in HDL therapy, the company is pursuing a range of HDL product candidates that are positioned to represent major advances in patient care and significant commercial opportunities in the treatment of cardiovascular and metabolic diseases. Cerenis has operations in Toulouse, France and Ann Arbor, Michigan. For more information please visit www.cerenis.com

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.